Evidence map›Paper›PMID 39796712›Full record

ArticleCancers2024

The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells.

Marieke Rosier, Anja Krstulović, Hyejeong Rosemary Kim, Nihardeep Kaur, Erhumuoghene Mary Enakireru, Deebie Symmes, Katalin Dobra, Ruihuan Chen, Caroline A Evans, Annica K B Gad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marieke RosierDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.
Anja KrstulovićDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.ORCID 0009-0008-6760-506X
Hyejeong Rosemary KimDepartment of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield S10 2RX, UK.
Nihardeep KaurDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.
Erhumuoghene Mary EnakireruDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.
Deebie SymmesAluda Pharmaceuticals, Inc., Menlo Park, CA 94025, USA.ORCID 0000-0003-3982-3170
Katalin DobraDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.
Ruihuan ChenAluda Pharmaceuticals, Inc., Menlo Park, CA 94025, USA.ORCID 0000-0002-0641-2132
Caroline A EvansSchool of Materials, Chemical and Biological Engineering, University of Sheffield, Sheffield S10 2TN, UK.ORCID 0000-0003-4356-9216
Annica K B GadDepartment of Oncology-Pathology, Karolinska Institutet, 171 64 Solna, Sweden.ORCID 0000-0002-1098-9129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

carcinomacell migrationepithelial-to-mesenchymal transitionextracellular matrixlung cancerTGF-β1vimentin interactomevimentin intermediate filaments

Identifiers

PMID39796712
PMCPMC11720119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.